Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease

G. Tzelepis, S. Komanapolli, Douglas Tyler, D. Vega, A. Fulambarker

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean ± SD) 69 ± 6 yrs; forced expiratory volume in one second (FEV1) 1.2 ± 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg + MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35% for GP+MP and 25% for either drug alone. These data suggest that nebulized gbcopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.

Original languageEnglish (US)
Pages (from-to)100-103
Number of pages4
JournalEuropean Respiratory Journal
Volume9
Issue number1
DOIs
StatePublished - Jan 1996
Externally publishedYes

Fingerprint

Glycopyrrolate
Metaproterenol
Chronic Obstructive Pulmonary Disease
Bronchodilator Agents
Inhalation
Spirometry
Forced Expiratory Volume
Double-Blind Method
Pharmaceutical Preparations

Keywords

  • Bronchitis
  • Bronchodilators
  • Glycopyrrolate

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. / Tzelepis, G.; Komanapolli, S.; Tyler, Douglas; Vega, D.; Fulambarker, A.

In: European Respiratory Journal, Vol. 9, No. 1, 01.1996, p. 100-103.

Research output: Contribution to journalArticle

Tzelepis, G. ; Komanapolli, S. ; Tyler, Douglas ; Vega, D. ; Fulambarker, A. / Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. In: European Respiratory Journal. 1996 ; Vol. 9, No. 1. pp. 100-103.
@article{caa5c928d574489b90372e99d4c0e9bc,
title = "Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease",
abstract = "We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean ± SD) 69 ± 6 yrs; forced expiratory volume in one second (FEV1) 1.2 ± 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg + MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35{\%} for GP+MP and 25{\%} for either drug alone. These data suggest that nebulized gbcopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.",
keywords = "Bronchitis, Bronchodilators, Glycopyrrolate",
author = "G. Tzelepis and S. Komanapolli and Douglas Tyler and D. Vega and A. Fulambarker",
year = "1996",
month = "1",
doi = "10.1183/09031936.96.09010100",
language = "English (US)",
volume = "9",
pages = "100--103",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "1",

}

TY - JOUR

T1 - Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease

AU - Tzelepis, G.

AU - Komanapolli, S.

AU - Tyler, Douglas

AU - Vega, D.

AU - Fulambarker, A.

PY - 1996/1

Y1 - 1996/1

N2 - We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean ± SD) 69 ± 6 yrs; forced expiratory volume in one second (FEV1) 1.2 ± 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg + MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35% for GP+MP and 25% for either drug alone. These data suggest that nebulized gbcopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.

AB - We assessed the bronchodilating effect of glycopyrrolate (GP) and compared it with that of metaproterenol (MP), alone and in combination (GP+MP), in patients with chronic obstructive pulmonary disease (COPD). In a double-blind study, 11 patients (aged (mean ± SD) 69 ± 6 yrs; forced expiratory volume in one second (FEV1) 1.2 ± 0.4 L) with stable COPD inhaled nebulized GP 1.0 mg, MP 15 mg, or GP 1.0 mg + MP 15 mg. Spirometry was performed before inhalation and at hourly intervals for 8 h after inhalation. It was found that GP produced a bronchodilating effect that was about equal to that of MP but lasted longer (8 vs 5 h). The combination of GP and MP produced a bronchodilating effect that was greater than that of either drug alone and was evident mostly during the effect of MP. The mean peak percentage improvement in FEV1 over baseline was 35% for GP+MP and 25% for either drug alone. These data suggest that nebulized gbcopyrrolate is an effective bronchodilator in some patients with chronic obstructive pulmonary disease. Concurrent administration of glycopyrrolate and metaproterenol produces additional bronchodilation that is primarily apparent during the bronchodilator effect of metaproterenol.

KW - Bronchitis

KW - Bronchodilators

KW - Glycopyrrolate

UR - http://www.scopus.com/inward/record.url?scp=0030030784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030030784&partnerID=8YFLogxK

U2 - 10.1183/09031936.96.09010100

DO - 10.1183/09031936.96.09010100

M3 - Article

VL - 9

SP - 100

EP - 103

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 1

ER -